Table 1 Demographic and baseline characteristics
100 mg/qd | 200 mg/qd | 300 mg/qd | 450 mg/qd | 600 mg/qd | 800 mg/qd | Total | ||
|---|---|---|---|---|---|---|---|---|
(n = 4) | (n = 3) | (n = 3) | (n = 4) | (n = 3) | (n = 3) | (N = 20) | ||
Gender | Male | 1 (25.0%) | 2 (66.7%) | 2 (66.7%) | 1 (25.0%) | 2 (66.7%) | 1 (33.3%) | 9 (45.0%) |
Female | 3 (75.0%) | 1 (33.3%) | 1 (33.3%) | 3 (75.0%) | 1 (33.3%) | 2 (66.7%) | 11 (55.0%) | |
Age (years) | Mean (SD) | 47.8 (6.45) | 52.0 (7.55) | 54.3 (6.11) | 61.3 (5.12) | 55.0 (6.00) | 47.0 (4.58) | 53.1 (7.32) |
ECOG score | 0 | 1 (25.0%) | 1 (33.3%) | 1 (33.3%) | 1 (25.0%) | 1 (33.3%) | 0 | 5 (25.0%) |
1 | 3 (75.0%) | 2 (66.7%) | 2 (66.7%) | 3 (75.0%) | 2 (66.7%) | 3 (100.0%) | 15 (75.0%) | |
Pathology | Adenocarcinoma | 3 (75.0%) | 3 (100.0%) | 3 (100.0%) | 4 (100.0%) | 3 (100.0%) | 3 (100.0%) | 19 (95.0%) |
Squamous | 1 (25.0%) | 0 | 0 | 0 | 0 | 0 | 1 (5.0%) | |
Stage | IV | 4 (100.0%) | 3 (100.0%) | 3 (100.0%) | 4 (100.0%) | 3 (100.0%) | 3 (100.0%) | 20 (100.0%) |
Brain metastases | Yes | 1 (25.0%) | 2 (66.7%) | 1 (33.3%) | 2 (50.0%) | 1 (33.3%) | 2 (66.7%) | 9 (45.0%) |
No | 3 (75.0%) | 1 (33.3%) | 2 (66.7%) | 2 (50.0%) | 2 (66.7%) | 1 (33.3%) | 11 (55.0%) | |
Number of metastatic lesions | 1 | 1 (25.0%) | 0 | 0 | 0 | 0 | 0 | 1 (5.0%) |
2 | 1 (25.0%) | 0 | 0 | 0 | 0 | 1 (33.3%) | 2 (10.0%) | |
3 | 1 (25.0%) | 1 (33.3%) | 2 (66.7%) | 2 (50.0%) | 2 (66.7%) | 1 (33.3%) | 9 (45.0%) | |
4 | 0 | 0 | 0 | 1 (25.0%) | 0 | 0 | 1 (5.0%) | |
5 | 0 | 2 (66.7%) | 1 (33.3%) | 1 (25.0%) | 1 (33.3%) | 0 | 5 (25.0%) | |
6 | 1 (25.0%) | 0 | 0 | 0 | 0 | 1 (33.3%) | 2 (10.0%) | |
Surgery | Yes | 2 (50.0%) | 2 (66.7%) | 1 (33.3%) | 2 (50.0%) | 2 (66.7%) | 1 (33.3%) | 10 (50.0%) |
No | 2 (50.0%) | 1 (33.3%) | 2 (66.7%) | 2 (50.0%) | 1 (33.3%) | 2 (66.7%) | 10 (50.0%) | |
Radiotherapy | Yes | 1 (25.0%) | 1 (33.3%) | 0 | 3 (75.0%) | 1 (33.3%) | 0 | 6 (30.0%) |
No | 3 (75.0%) | 2 (66.7%) | 3 (100.0%) | 1 (25.0%) | 2 (66.7%) | 3 (100.0%) | 14 (70.0%) | |
Chemotherapy and targeted therapy | Yes | 4 (100.0%) | 3 (100.0%) | 3 (100.0%) | 4 (100.0%) | 3 (100.0%) | 3 (100.0%) | 20 (100.0%) |
No | 0 | 0 | 0 | 0 | 0 | 0 | 0 |